{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T11:43:00Z","timestamp":1725622980100},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s10585-012-9504-2","type":"journal-article","created":{"date-parts":[[2012,6,30]],"date-time":"2012-06-30T07:17:24Z","timestamp":1341040644000},"page":"801-805","source":"Crossref","is-referenced-by-count":13,"title":["Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients"],"prefix":"10.1007","volume":"29","author":[{"given":"Nicola","family":"Mozzillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,1]]},"reference":[{"key":"9504_CR1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.6004\/jnccn.2009.0022","volume":"7","author":"LA Fecher","year":"2009","unstructured":"Fecher LA, Flaherty KT (2009) Where are we with adjuvant therapy of stage III and IV melanoma in 2009? J Natl Compr Cancer Netw 7:295\u2013304","journal-title":"J Natl Compr Cancer Netw"},{"key":"9504_CR2","unstructured":"Wheatley K, Ives N, Eggermont A, et al. (2007) Interferon-\u03b1 as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol. ASCO annual meeting proceedings Part I 25: Abstract 8526, 2007 (18S (June 20 Supplement))"},{"key":"9504_CR3","doi-asserted-by":"crossref","unstructured":"Mocellin S, Pasquali S, Rossi CR, et al. (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst","DOI":"10.1093\/jnci\/djq009"},{"key":"9504_CR4","first-page":"4713","volume":"6","author":"P Salmoniere de La","year":"2000","unstructured":"de La Salmoniere P, Grob JJ, Dreno B et al (2000) White blood cell count: a prognostic factor and possible subset indicator of optimal treatment with low-dose adjuvant interferon in primary melanoma. Clin Cancer Res 6:4713\u20134718","journal-title":"Clin Cancer Res"},{"key":"9504_CR5","doi-asserted-by":"crossref","unstructured":"Stuckert JJ II, Tarhini AA, Lee S, et al (2007) Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696. J Clin Oncol (Meet Abstr) 25:8506","DOI":"10.1200\/jco.2007.25.18_suppl.8506"},{"key":"9504_CR6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","volume":"354","author":"H Gogas","year":"2006","unstructured":"Gogas H, Ioannovich J, Dafni U et al (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709\u2013718","journal-title":"N Engl J Med"},{"key":"9504_CR7","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1200\/JCO.2005.05.2498","volume":"24","author":"SJ Moschos","year":"2006","unstructured":"Moschos SJ, Edington HD, Land SR et al (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24:3164\u20133171","journal-title":"J Clin Oncol"},{"key":"9504_CR8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1479-5876-6-62","volume":"6","author":"PA Ascierto","year":"2008","unstructured":"Ascierto PA, Kirkwood JM (2008) Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 6:62","journal-title":"J Transl Med"},{"key":"9504_CR9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1479-5876-9-52","volume":"9","author":"DL Simons","year":"2011","unstructured":"Simons DL, Lee G, Kirkwood JM et al (2011) Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med 9:52","journal-title":"J Transl Med"},{"key":"9504_CR10","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1158\/1078-0432.CCR-06-1387","volume":"13","author":"W Wang","year":"2007","unstructured":"Wang W, Edington HD, Rao UN et al (2007) Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 13:1523\u20131531","journal-title":"Clin Cancer Res"},{"key":"9504_CR11","doi-asserted-by":"crossref","first-page":"8314","DOI":"10.1158\/1078-0432.CCR-08-0705","volume":"14","author":"W Wang","year":"2008","unstructured":"Wang W, Edington HD, Rao UN et al (2008) Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res 14:8314\u20138320","journal-title":"Clin Cancer Res"},{"key":"9504_CR12","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.4049\/jimmunol.175.8.5058","volume":"175","author":"T Hiura","year":"2005","unstructured":"Hiura T, Kagamu H, Miura S et al (2005) Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol 175:5058\u20135066","journal-title":"J Immunol"},{"key":"9504_CR13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.192.2.303","volume":"192","author":"T Takahashi","year":"2000","unstructured":"Takahashi T, Tagami T, Yamazaki S et al (2000) Immunologic self-tolerance maintained by CD25+\u00a0CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303\u2013310","journal-title":"J Exp Med"},{"key":"9504_CR14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ni759","volume":"3","author":"J Shimizu","year":"2002","unstructured":"Shimizu J, Yamazaki S, Takahashi T et al (2002) Stimulation of CD25+\u00a0CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3:135\u2013142","journal-title":"Nat Immunol"},{"key":"9504_CR15","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057\u20131061","journal-title":"Science"},{"key":"9504_CR16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1158\/1078-0432.CCR-06-2820","volume":"13","author":"EM Gabriel","year":"2007","unstructured":"Gabriel EM, Lattime EC (2007) Anti-CTL-associated antigen 4: are regulatory T cells a target? Clin Cancer Res 13:785\u2013788","journal-title":"Clin Cancer Res"},{"key":"9504_CR17","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.4049\/jimmunol.173.2.1444","volume":"173","author":"M Viguier","year":"2004","unstructured":"Viguier M, Lemaitre F, Verola O et al (2004) Foxp3 expressing CD4+\u00a0CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444\u20131453","journal-title":"J Immunol"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-012-9504-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-012-9504-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-012-9504-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T04:06:21Z","timestamp":1594353981000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-012-9504-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,1]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["9504"],"URL":"https:\/\/doi.org\/10.1007\/s10585-012-9504-2","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,1]]}}}